Genetic Signatures (GSS), an ASX-listed company, is a specialist molecular diagnostics (MDx) company on the development and commercialisation of its proprietary platform technology, 3Baseâ„¢. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the EasyScreenâ„¢ brand.
ASX Code | GSS |
Website | http://www.geneticsignatures.com |
Industry/Sector | Life Sciences Tools & Services |
Market Cap ($M) | 138 |
GSS Share Price | $0.740 |
Day High | $0.750 |
Day Low | $0.740 |
Last Close | $0.740 |
GSS Share Price Movement | - ( No change ) |
Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
---|---|---|---|---|---|---|---|
Final | 0.12¢ | 0% | 27 Aug 1996 | 30 Sep 1996 | $0.740 | $0.705 | - |
See all dividends from Genetic Signatures Limited (GSS) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Headline | Annoucement date/time+ | Price at announcement+ | Current price+ | Price 7D Avg | Gain/Loss |
---|---|---|---|---|---|
Ceasing to be a substantial holder | 7 May 2024 4:44PM | $0.720 | $0.740 | $0.705 | risen by 2.78% |
Application for quotation of securities - GSS | 3 May 2024 1:46PM | $0.705 | $0.740 | $0.705 | risen by 4.96% |
Final Director's Interest Notice | 30 Apr 2024 6:22PM | $0.695 | $0.740 | $0.705 | risen by 6.47% |
See all ASX announcements from Genetic Signatures Limited (GSS) or use our ASX Announcements tool to search for announcements across all ASX-listed securities.
Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
---|---|---|---|---|---|---|---|
2023A | -$14.05 | -$9.60 | -564.60% | 0.00 | 0.00 | 0.00% | 0.0% |
2022A | $3.06 | $2.10 | 74.60% | 63.70 | 0.00 | 0.00% | 0.0% |
2021A | $1.76 | $1.20 | -173.30% | 149.40 | 0.00 | 0.00% | 0.0% |
Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
---|---|---|---|---|---|---|---|---|---|---|
2021 A | 2022 A | 2023 A | 2021 A | 2022 A | 2023 A | 2021 A | 2022 A | 2023 A | ||
Genetic Signatures (GSS) | $139M | -5.6456 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
---|---|---|---|---|
Company | 0.00 | 0.00 | 2.53 | 0.00 |
Market | 0.46 | 14.90 | 1.10 | 1.15 |
Sector | 1.38 | 20.80 | 1.85 | 0.94 |
Name | Position | Start Date |
---|---|---|
Mr Michael Anton Aicher | Executive Director - US Operations | 16 May 2014 |
Dr Neil Gunn | Executive Director, Interim CEO | 6 Apr 2021 |
Dr Nicholas Samaras | Non-Executive Chairman, Non-Executive Director | 22 Jan 2008 |
Dr Anthony (Tony) Radford | Non-Executive Director | 15 Sep 2015 |
Ms Caroline Waldron | Non-Executive Director | 13 May 2022 |
Mr Stephane Chatonsky | Non-Executive Director | 4 Dec 2023 |
Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
---|---|---|---|---|---|---|
27 Feb 2024 | CHATONSKY, Stephane | Buy | Indirect Shares | 112,733 | $0.520 | $58,621.160 |
25 Jan 2024 | SAMARAS, Nicholas | Issued | Direct Shares | 209,476 | $0.370 | $77,506.120 |
25 Jan 2024 | CHATONSKY, Stephane | Issued | Indirect Shares | 48,767 | $0.370 | $18,043.790 |
See all changes in directors' interest & trades for Genetic Signatures Limited (GSS) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
Name | Position |
---|---|
Karl David Pechmann | Chief Financial Officer,Chief Operating Officer,Company Secretary |
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Genetic Signatures Limited (GSS). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
Holding | Name |
---|---|
37,500,000 (26.15%) | Asian Union Investment Pty Limited |
21,462,703 (14.97%) | Perennial Value Management Limited |
9,876,864 (6.89%) | FIL Limited and the entities |
Date | Event |
---|---|
20 February 2025 | Report (Interim) |
02 September 2024 | Report (Prelim) |
29 August 2024 | Report (Annual) |
29 August 2024 | Report (Prelim) |
Genetic Signatures Limited's (GSS) current share price is $0.74. This constitutes a price movement of 4.96% when compared to the share price 7 days ago and is -1.33% below GSS's 12-month high of $0.75 per share. Prices are delayed by at least 20 minutes.
Relative to the previous close share price of $0.74, Genetic Signatures Limited's (GSS) current share price of $0.74 constitutes a movement of or 0%. Genetic Signatures Limited's (GSS) share price movement is 4.96% when compared to 7 days ago and is -1.33% below GSS's 52-week high of $0.75.
Genetic Signatures Limited's (GSS) 52-week high is $0.75 which was reached on 6 May 2024. Relative to this, GSS's current share price of $0.74 constitutes a -$0.01 or -1.33% drop since that high of $0.75 per GSS share.
Genetic Signatures Limited's (GSS) 52-week low is $0.41 which was reached on 2 Jan 2024. Relative to this, GSS's current share price of $0.74 constitutes a $0.34 or 82.72% gain since that low of $0.41 per GSS share.
Over the last 12 months, Genetic Signatures Limited (GSS) has a daily average trading volume of 79,066 GSS shares per day.
Genetic Signatures Limited (GSS) has a current dividend yield of n/a this year. Last year's dividend yield was 0%. The dividend yield for GSS is a ratio that tells you the percentage of Genetic Signatures Limited's (GSS) share price that it pays out in dividends each year.
Genetic Signatures Limited (GSS) last dividend payment was $0.00 per share and was paid on 30 Sep 1996. This last GSS dividend included 0% franking.
Genetic Signatures Limited (GSS) will release its next Annual Report on 29 August 2024. Genetic Signatures Limited's (GSS) last annual report was released on 31 Aug 2023. Click here to view Genetic Signatures Limited's (GSS) last annual report.
Genetic Signatures Limited (GSS) is classified as Health Care. Other companies in this sector include CSL Limited (CSL), ResMed Inc. (RMD), Cochlear Limited (COH), and Fisher & Paykel Healthcare Corporation Limited (FPH).
The price-to-earnings (P/E) ratio for Genetic Signatures Limited (GSS) is 0. The price-to-earnings ratio, also known as P/E ratio, P/E, or PER, is the ratio of Genetic Signatures Limited's (GSS) share price to its earnings per GSS share.
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.